You are here

eWear Seminar: Smart Contact Lens for Diagnostic and Therapeutic Applications

Wednesday, February 6, 2019 - 4:00pm to 4:45pm
Smart Contact Lens for Diagnostic and Therapeutic Applications

Abstract: Among various wearable devices, a smart contact lens is especially noticeable for healthcare applications, because it can be used as an efficient interface between an electronic device and the human body. Here, we developed a smart electrochemical contact lens with novel functionality for continuous monitoring and treatment of diabetic retinopathy. The contact lens device, built on a standard biocompatible polymer, contains ultrathin, flexible electrical circuits and a microcontroller chip for real-time electrochemical biosensing, on-demand controlled drug delivery, remote power management and wireless data communication. In animal tests using diabetic model rabbits, we could measure tear glucose levels that were consistent with those by the conventional invasive blood-glucose tests and allow drugs to be released from reservoirs for the treatment of diabetic retinopathy. In addition, we developed smart photonic contact lens for theranostic applications to diabetes. The smart photonic contact lens could measure the glucose levels in the body fluid and be used for diabetic photomodulation therapy. Furthermore, this smart contact lens platform was successfully applied for a proof of concept to monitor the intraocular pressure of glaucoma patients. Taken together, we confirmed the feasibility of smart contact lenses for non-invasive and real-time management of diabetes, diabetic retinopathy and various ocular diseases. This presentation will provide the current state-of-the-art smart contact lens for further clinical applications.

Biography: After graduation from Kyeongnam Science Highschool in 2 years, Sei Kwang Hahn obtained his B.S., M.S., and Ph.D. in the Department of Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology (KAIST). As the youngest Ph.D. at LG Chemical Group in 1996, he started his research on biodegradable polymer and then sustained release formulation of human growth hormone, which was successfully commercialized in Korea under the trade name of Declage® in 2007. Starting from 2001, he did his post-doctoral research with one of the founders of biomaterials fields, Prof. Allan Hoffman, in the Department of Bioengineering at the University of Washington. After that, he worked for long acting formulation of various biopharmaceuticals at the Roche Group, Chugai Pharmaceutical Co. in Japan for more than three years. Since 2005, he has worked as a professor in the Department of Materials Science and Engineering, and an adjunct professor in the Department of Creative IT Engineering, and School of Interdisciplinary Bioscience and Bioengineering at POSTECH. He was a consultant for Johnson & Johnson Co. in New Jersey in 2008 and made a collaboration project contract with Hoffman-La Roche Co. in 2009. From 2012, he joined in the Wellman Center for Photomedicine, Harvard Medical School and Massachusetts General Hospital for his sabbatical research supported by LG Yeonam Fellowship. He received the Controlled Release Society Award in 2018, the Minister of Health and Welfare Award in 2017, the Korean President Award in 2015 and the Korean Minister of Education Award in 2013. He published more than 120 SCI journal papers including Nature Photonics, Nature Communications, Progress in Polymer Science, Advanced Materials, and ACS Nano, and filed more than 120 Korean and international patents. He founded a bio-venture company of “PHI BioMed” in 2014. He is an editorial board member of ACS Biomaterials Science and Engineering, ACS Applied Bio Materials, Biomacromolecules, Applied Biosciences and Bioengineering and Biomaterials Research. He is one of the Samsung Future Technology Committee Members since 2016 and the Presidential Advisory Council Members on Science and Technology since 2017.